Tech Center 1600 • Art Units: 1625 1631 1692
This examiner grants 58% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17773404 | MrgprX2 Antagonists and Uses Thereof | Non-Final OA | Dermira, Inc. |
| 18078269 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | Non-Final OA | Deciphera Pharmaceuticals, LLC |
| 18191574 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | Non-Final OA | DANA-FARBER CANCER INSTITUTE, INC. |
| 17912341 | COMBINATION THERAPY WITH A MUTANT IDH INHIBITOR AND A BCL-2 INHIBITOR | Non-Final OA | Board of Regents, The University of Texas System |
| 18546245 | TREATING VIRAL INFECTION WITH NMD INHIBITORS | Non-Final OA | The Cleveland Clinic Foundation |
| 18063841 | METHODS OF PRODUCING GLYCIDYL NITRATE AND RELATED SYSTEMS | Final Rejection | Northrop Grumman Systems Corporation |
| 18144990 | METHOD AND PHARMACEUTICAL COMPOSITION FOR TREATING OR ALLEVIATING GLIOMAS IN A SUBJECT | Non-Final OA | Zhejiang University |
| 17759480 | BERBERINE COMPOUNDS, BERBERINE COMPOSITIONS, AND METHODS FOR ADMINISTRATION THEREOF | Final Rejection | Dignity Health |
| 17957539 | PYRAZOLYLPROPANAMIDE COMPOUNDS AND USES THEREOF FOR TREATMENT OF PROSTATE CANCER | Non-Final OA | University of Tennessee Research Foundation |
| 17800516 | Inhibitors of Human Herpesviruses | Final Rejection | The Governors of the University of Alberta |
| 18573074 | SULFOXIMINE COMPOUND AND USE THEREOF | Non-Final OA | USYNOVA PHARMACEUTICALS LTD. |
| 18573222 | SALT AND CRYSTAL FORMS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR | Non-Final OA | Blueprint Medicines Corporation |
| 18540293 | SUBSTITUTED DIARYL COMPOUND AS WELL AS PREPARATION METHOD AND APPLICATION THEREOF | Non-Final OA | SHANDONG FIRST MEDICAL UNIV & SHANDONG ACADEMY OF MEDICAL SCIENCES |
| 18540119 | USE OF ATR INHIBITORS IN COMBINATION WITH PARP INHIBITORS FOR TREATING CANCER | Non-Final OA | Repare Therapeutics Inc. |
| 18569414 | CRYSTALLINE FORMS OF ISOXAZOLINE COMPOUND | Non-Final OA | ELANCO US, INC. |
| 18569519 | SUBSTITUTED PYRAZOLO [1,5-A]PYRIMIDINE-7-AMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | Non-Final OA | Carrick Therapeutics Limited |
| 17771204 | BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER | Non-Final OA | C4 THERAPEUTICS, INC. |
| 18332851 | PROTEASE INHIBITORS FOR TREATMENT OF CORONAVIRUS INFECTIONS | Non-Final OA | THE SCRIPPS RESEARCH INSTITUTE |
| 17791680 | NOVEL USE OF MULTIKINASE INHIBITOR | Final Rejection | TransThera Sciences (Nanjing), Inc. |
| 18549778 | USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER | Non-Final OA | Impact Therapeutics (Shanghai), Inc |
| 18546003 | 6-METHYLURACIL DERIVATIVES WITH ANTICHOLINESTERASE ACTIVITY AND THEIR USE | Non-Final OA | AVVA PHARMACEUTICALS LTD |
| 18263442 | CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Non-Final OA | INNOVSTONE THERAPEUTICS LIMITED |
| 18020980 | DOSAGE FORM COMPOSITIONS COMPRISING AN INHIBITOR OF BTK AND MUTANTS THEREOF | Final Rejection | Newave Pharmaceutical Inc. |
| 18209515 | ADHESIVE PHOTOPROTECTIVE COMPOUNDS AND USES THEREOF | Non-Final OA | SKINOSIVE |
| 18266793 | KINASE INHIBITORS AND USES THEREOF | Non-Final OA | MOSAICA MEDICINES, INC. |
| 17629966 | SELECTIVE BCRP/ABCG2 TRANSPORTER INHIBITORS AS AGENTS TO ABOLISH RESISTANCE TO ANTI-CANCER AGENTS | Non-Final OA | UNIVERSITE CLAUDE BERNARD LYON 1 |
| 18022963 | USE OF THIAZOLIDES AGAINST CORONAVIRUSES | Non-Final OA | Romark Laboratories, L.C. |
| 18040824 | ATR INHIBITORS AND USES THEREOF | Non-Final OA | ANTENGENE DISCOVERY LIMITED |
| 17927073 | COMPOSITIONS OF CANNABINOIDS AND METHODS OF USING SAME | Non-Final OA | ASANA BIO GROUP LTD. |
| 17920244 | TETRAHYDROISOQUINOLINE COMPOUNDS AS NRF2 ACTIVATORS | Non-Final OA | C4X Discovery Limited |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy